What could happen to people who rely on concentrated 7-hydroxymitragynine or kratom every day—and what they can do now to prepare.
The federal government is moving aggressively against concentrated 7-hydroxymitragynine (7-OH) products, and people who use them regularly are understandably asking a question that often gets overlooked in the policy debate:
What happens to the people who are physically dependent on these products when the supply disappears?
That question matters because 7-OH is not simply another herbal ingredient. It acts at the mu-opioid receptor and can produce opioid-like effects, including tolerance, physical dependence and withdrawal. The FDA describes concentrated 7-OH products as potent opioid products and has received reports of addiction and withdrawal symptoms among users. U.S. Food and Drug Administration+1
At the same time, the federal action is more narrowly targeted than headlines such as “DEA bans kratom” might suggest.
What the DEA is actually proposing
On July 1, 2026, the Drug Enforcement Administration announced its intent to temporarily place 7-hydroxymitragynine above a specified threshold into Schedule I of the Controlled Substances Act. The Federal Register notice describes a threshold of more than 0.050% 7-OH in botanical kratom on a dry-weight basis, or products containing more than 0.050% by weight/volume or more than 1 milligram of 7-OH in certain other products. DEA+1
The proposal is specifically aimed at concentrated, enhanced and synthetic products rather than ordinary botanical kratom containing only naturally occurring trace amounts of 7-OH. DEA has repeatedly emphasized that distinction. DEA+1
There is an important procedural wrinkle, however. The July notice was a notice of intent to issue a temporary scheduling order, not itself the final temporary scheduling order. The notice said that the order would not be issued before August 5. As of August 27, the Federal Register record still shows the 7-OH action as the July notice of intent, while the separate scheduling order for three related compounds became effective August 26. GovInfo+1
HHS also extended the comment period concerning the proposed 7-OH threshold on August 26, 2026. That does not mean the government has abandoned the scheduling effort; it means the threshold question remains under consideration. FFederal Register Public Inspection
What this could mean for someone who is physically dependent
For a person using concentrated 7-OH every day, the biggest immediate concern may not be criminal law. It may be withdrawal.
Someone who takes 7-OH frequently can develop tolerance and physical dependence. If access suddenly becomes difficult, a person may experience symptoms such as:
- Restlessness and agitation
- Anxiety or irritability
- Muscle and body aches
- Sweating or chills
- Runny nose
- Diarrhea or gastrointestinal distress
- Insomnia
- Fatigue
- Depressed mood
- Strong cravings
- Other opioid-like withdrawal symptoms
The FDA has specifically reported withdrawal symptoms associated with 7-OH products, including restlessness, body aches, fatigue, irritability and cold sweats. Research on kratom withdrawal has also documented symptoms resembling opioid withdrawal, although the intensity and duration can vary considerably between individuals. U.S. Food and Drug Administration+2
The experience of someone using ordinary kratom leaf may also be very different from that of someone consuming concentrated 7-OH tablets, extracts, shots or other enhanced products.
That distinction is important.
7-OH dependence and kratom dependence are not necessarily the same thing
“Kratom” is often treated as though it describes one standardized drug. It does not.
Natural kratom contains many alkaloids, with mitragynine being the predominant alkaloid and 7-OH occurring naturally only in relatively small amounts. FDA notes that natural kratom leaves generally contain less than 2% of their total alkaloid content as 7-OH, while concentrated commercial products can contain substantially elevated amounts.U.S. Food and Drug Administration+1
That means two people can both say they “use kratom” while having dramatically different levels of opioid exposure.
Someone drinking relatively small amounts of traditional leaf preparation is not necessarily in the same physiological situation as someone taking multiple high-potency 7-OH tablets throughout the day.
The distinction also matters when considering withdrawal treatment.
The biggest concern: an abrupt supply shock
If concentrated 7-OH products become substantially harder to obtain, some dependent users may try to stop abruptly.
That could create a difficult situation.
A person who has been using 7-OH several times a day may not have access to a physician, addiction specialist or clinician familiar with 7-OH withdrawal. They may instead try to switch rapidly to another product, buy whatever is available on the illicit market, or return to conventional opioids.
That last possibility deserves particular attention.
Someone who has developed opioid tolerance through 7-OH or kratom may have an unpredictable tolerance level, particularly if they stop for a period and subsequently return to opioids. Illicit opioid products can also contain fentanyl or other substances, making a return to opioid use potentially much more dangerous than the person realizes.
A disruption in the 7-OH supply should therefore be viewed as a potential treatment-access problem, not simply a drug-enforcement problem.
There is already evidence that clinicians can treat 7-OH dependence
The medical literature is still developing, but it is no longer accurate to say that there is no clinical experience treating problematic 7-OH use.
A 2026 retrospective case series examined nine people receiving buprenorphine for problematic 7-OH use. Eight of the nine patients successfully initiated and stabilized on treatment, and the researchers reported improvement in symptoms at follow-up. The study used both standard and low-dose initiation strategies. PubMed
Another 2026 case report described a patient with high-dose chronic 7-OH use who developed acute withdrawal and was treated with buprenorphine-naloxone and supportive medications before being referred for ongoing treatment. PubMed
There is also older clinical experience with kratom dependence. Case series and systematic reviews have described the use of buprenorphine/naloxone in people experiencing kratom dependence and withdrawal. PubMed+1
But this is an important caveat: these studies are largely case reports, case series and retrospective observations. There is not yet the same large clinical-trial evidence base for treating 7-OH dependence that exists for conventional opioid use disorder.
Buprenorphine may become increasingly important
For people who meet criteria for opioid use disorder, medications such as buprenorphine and methadone are established treatments for opioid use disorder.
Buprenorphine reduces opioid withdrawal and cravings and is widely used as medication treatment for opioid use disorder. SAMHSA describes it as an FDA-approved medication for OUD. SAMHSA
Methadone is another FDA-approved medication for OUD and is a long-acting opioid agonist that reduces cravings and withdrawal. SAMHSA
However, someone dependent on 7-OH should not attempt to self-prescribe or self-induct buprenorphine based on an internet dosing schedule.
The timing of buprenorphine is clinically important because taking it while significant opioid activity is still present can, in some circumstances, cause precipitated withdrawal. SAMHSA specifically advises that patients beginning buprenorphine should be assessed and should be in opioid withdrawal before conventional initiation. SAMHSA
The situation can be more complicated with concentrated 7-OH because its pharmacology and withdrawal patterns are still being studied.
A clinician who understands addiction medicine can determine whether medication treatment is appropriate and which initiation strategy makes sense.
What people using 7-OH can do now
The most useful response to the DEA action is not panic. It is preparation.
People who use concentrated 7-OH regularly should consider talking to a healthcare professional before they run out.
That conversation can include:
- How frequently 7-OH is being used
- The approximate amount being used
- Whether the person is also using kratom leaf, prescription opioids, fentanyl, alcohol, benzodiazepines or other substances
- Whether withdrawal occurs between doses
- Whether use has escalated over time
- Whether cravings or inability to cut down are present
- Whether there is an underlying pain condition or another reason for continued use
- Whether medication treatment for opioid use disorder is appropriate
People should also be honest about what product they are actually taking. Saying “I use kratom” may not give a clinician enough information if the product is actually a concentrated 7-OH tablet or extract.
Do not assume that ordinary kratom is a guaranteed substitute
One understandable reaction to the proposed scheduling action is:
“I’ll just switch from 7-OH to regular kratom.”
That may or may not work, and it should not be assumed to be a medically equivalent substitution.
The amount of 7-OH in botanical kratom is much lower than in many concentrated commercial products, and commercial products themselves can vary substantially in composition and potency. FDA has also warned about variability and safety concerns involving kratom products generally. U.S. Food and Drug Administration+1
For someone with substantial physical dependence, abruptly replacing a concentrated 7-OH product with an unpredictable amount of botanical kratom could result in inadequate opioid effect and significant withdrawal.
It could also encourage escalating use or switching among increasingly potent products.
Another concern is the illicit market
Whenever a widely available psychoactive product becomes restricted, some users will seek alternatives outside regulated channels.
That creates another layer of risk.
A person who cannot find their usual 7-OH product may encounter products with inaccurate labeling, unexpected concentrations or other active ingredients. FDA has already expressed concern about concentrated 7-OH products and has taken enforcement actions against companies selling them. In December 2025, federal authorities announced the seizure of approximately 73,000 units of concentrated 7-OH products from three warehouses. U.S. Food and Drug Administration
The federal government is therefore already disrupting portions of the concentrated 7-OH market.
For dependent users, that makes continuity of legitimate medical care especially important.
What withdrawal may look like
Withdrawal is not necessarily identical for everyone.
People withdrawing from kratom have reported symptoms including muscle aches, diarrhea, runny nose, sweating, restlessness, irritability, anxiety, depressed mood and fatigue. A systematic review found that chronic kratom use can produce tolerance, dependence and withdrawal after cessation. PubMed+1
Concentrated 7-OH may produce a more distinctly opioid-like withdrawal syndrome because of its stronger mu-opioid activity. Recent case reports specifically describe clinically significant withdrawal following chronic high-dose 7-OH exposure. PPubMed+1
The key point is that withdrawal is a medical issue, not a moral failure.
If someone is physically dependent, repeatedly trying to stop and then returning to the drug does not necessarily mean they lack willpower. It may mean that their brain and body have adapted to regular opioid-receptor stimulation.
When withdrawal becomes an emergency
Most withdrawal symptoms are extremely uncomfortable but are not by themselves usually life-threatening in the same way as some other drug withdrawals.
However, people using 7-OH may also be using other substances, may have underlying medical conditions, or may be exposed to products of uncertain composition.
Emergency medical attention is appropriate for symptoms such as:
- Trouble breathing
- Blue or gray lips or skin
- Severe confusion or inability to stay awake
- Seizures
- Chest pain
- Severe dehydration
- Uncontrolled vomiting
- Suicidal thoughts or an immediate risk of self-harm
Because 7-OH is an opioid-like substance, combining it with other central nervous system depressants can increase risk. FDA has warned about opioid-related effects including sedation and respiratory depression associated with kratom-related products. U.S. Food and Drug Administration
Naloxone is still worth having
Anyone regularly using an opioid-like substance should consider having naloxone (Narcan) available, particularly if other opioids or sedating substances are involved.
Naloxone is intended to reverse opioid overdose and is not a treatment for withdrawal or dependence. It is an emergency safety measure.
People who live with someone using 7-OH should also know the signs of opioid overdose and how to administer naloxone.
The policy debate should include the people already dependent
There are legitimate public-health reasons for concern about concentrated 7-OH. FDA describes 7-OH as a potent mu-opioid agonist and has documented concerns involving addiction, withdrawal and other adverse effects.U.S. Food and Drug Administration+1
But enforcement alone does not solve dependence.
If a person is physically dependent on 7-OH today, scheduling can change the legal status and availability of the product—but it does not instantly eliminate the person’s physiological dependence.
That means an effective public-health response needs two components:
Reduce exposure to dangerous concentrated products, while simultaneously expanding access to treatment for the people who are already dependent on them.
That includes clinicians who understand 7-OH and kratom, access to evidence-based addiction treatment, affordable medication, overdose prevention, and nonjudgmental care.
What happens next?
The immediate federal picture is still developing.
The DEA’s July 2026 action proposed temporary Schedule I control for 7-OH above the specified threshold. The proposed threshold is intended to distinguish concentrated/enhanced products from botanical kratom containing only trace naturally occurring 7-OH. GovInfo
Meanwhile, DEA has already temporarily placed three related compounds—mitragynine pseudoindoxyl, MGM-15 and MGM-16—into Schedule I, effective August 26, 2026. Federal Register+1
HHS is also continuing to consider public input regarding the proposed 7-OH threshold. Federal Register Public Inspection
So consumers should be cautious about statements claiming that “all kratom is now federally illegal.” That is not what the current federal action says.
The focus of the announced 7-OH action is concentrated or enhanced 7-OH above the specified threshold, not ordinary botanical kratom containing naturally occurring trace levels below that threshold. State laws can be different, however, and federal policy may continue to change. DEA+1
The bottom line for people who are dependent
If you are using 7-OH every day and need it to feel normal, avoid withdrawal, sleep, work or function, now is a good time to talk to a medical professional rather than waiting for the market to change around you.
You do not need to wait until the product is unavailable.
You do not need to describe yourself as an “addict” to ask for help.
And you should not assume that abruptly stopping, switching products, or trying to manage severe withdrawal alone is the safest approach.
There is emerging evidence that clinicians can successfully treat problematic 7-OH and kratom use, including with medications used for opioid use disorder in appropriate patients. The evidence base is still developing, but the first 2026 reports specifically involving 7-OH are encouraging. PubMed+2
For people who are dependent, the most important message is simple:
The DEA’s scheduling action may change what is available—but it does not change the fact that dependence is a medical condition that deserves medical treatment.
References
- U.S. Drug Enforcement Administration. “DEA to Temporarily Schedule 7-OH and Related Substances to Protect Public Safety.” July 1, 2026. DEA
- Federal Register. “Schedules of Controlled Substance: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I.” 91 FR 40917, July 6, 2026. GovInfo
- U.S. Department of Health and Human Services. “HHS, FDA Commend DEA Action Against Dangerous Enhanced 7-OH Products.” July 1, 2026. HHHS.gov
- U.S. Food and Drug Administration. “Hiding in Plain Sight: 7-OH Products.” Updated July 13, 2026. U.S. Food and Drug Administration
- U.S. Food and Drug Administration. “Products Containing 7-OH Can Cause Serious Harm.” U.S. Food and Drug Administration
- U.S. Food and Drug Administration. 7-Hydroxymitragynine (7-OH): An Assessment of the Scientific Data and Toxicological Concerns Around an Emerging Opioid Threat. U.S. Food and Drug Administration
- U.S. Department of Justice. “Justice Department Announces Emergency Scheduling of Three Potent Opioid Compounds.” August 25, 2026. DDepartment of Justice
- Federal Register. “Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I.” Effective August 26, 2026. FFederal Register
- SAMHSA. “What is Buprenorphine?” SSAMHSA
- SAMHSA. “What is Methadone?” SSAMHSA
- Avery et al. “Buprenorphine for the Management of 7-Hydroxymitragynine (7-OH) Use: A Retrospective Case Series.” Journal of Addiction Medicine, 2026. PPubMed
- Kratom Withdrawal: A Systematic Review with Case Series. Journal of Psychoactive Drugs, 2019. PPubMed
- Management of kratom dependence with buprenorphine/naloxone in a veteran population. Journal of Addiction Medicine, 2021. PPubMed
- A Case of 7-Hydroxymitragynine Use Disorder Treated With Buprenorphine. Journal of Addiction Medicine, 2026. PPubMed
This article is for educational purposes and is not a substitute for individualized medical or legal advice. People with significant 7-OH or kratom dependence should speak with a qualified healthcare professional about withdrawal and treatment planning.